Skip to main content
Equibles
STOK logo

STOK · Stoke Therapeutics, Inc.

Track STOK — free

Use STOK with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$30.43 -0.46 (-1.49%)
Russell 2000 member Rebalance outlook locked
Market Cap
$1.96B
Shares
64.53M

STOK metrics

64 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$30.89
Market cap
$1.96B

Price action

19 metrics
Price change (1W)
-7.7%
Price change (30D)
+4.5%
Price change (3M)
+7.7%
Price change (6M)
-8.6%
Price change (YTD)
-2.7%
Price change (1Y)
+56.3%
Trailing year
Price change (5Y)
+16.6%
52-week high
$38.35
52-week low
$19.59
Change from 52-week high
-19.5%
Change from 52-week low
+57.7%
Annualized volatility
59.2%
Beta
0.9
RSI (14D)
45.4
Price vs SMA 50
-1.0%
Price vs SMA 200
-3.2%
Avg volume (3M)
868,076
Relative volume
0.8
Average dollar volume
$27.09M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
64.53M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
71.1×
reciprocal yield 1.4%
P / book
5.7
reciprocal yield 17.6%
FCF yield
-9.2%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-10.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-03

Profitability

9 metrics
Gross margin
—
Operating margin
-809.7%
Trailing 12 months
Net margin
-753.6%
Gross profit (TTM)
—
Operating profit (TTM)
−$223.38M
Net income (TTM)
−$207.90M
Trailing 12 months
Diluted EPS (TTM)
$-3.34
FCF margin
-654.9%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$144.44

Growth

11 metrics
Revenue growth YoY
-32.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$27.59M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+13.1%
Year over year · more shares
Revenue CAGR (3Y)
+145.9%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-60.2%
Return on assets
-52.8%
Debt / equity
—
Current ratio
7.7
EBITDA (TTM)
—
Free cash flow (TTM)
−$180.68M
Quick ratio
7.7
Interest coverage
-4,963.9
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$110.00M
Latest balance sheet
Cash & equivalents
$110.00M
Total assets
$393.97M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$177.99M
Capital expenditures (TTM)
$2.69M
R&D (TTM)
$168.56M
SG&A (TTM)
$82.40M
Stock compensation (TTM)
$37.44M
R&D / revenue
611.0%
Stock compensation / revenue
135.7%

Ownership (13F)

3 metrics
13F filers
199
13F filer change QoQ
0
Institutional ownership
118.2%

Short interest

3 metrics
Short interest
20.1%
Latest settlement · 12.7 days to cover
Days to cover
12.7d
Short-squeeze score
73 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$1.13M
Insider-sentiment score
28 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1623526 CUSIP 86150R107 13F (30d) 180 filings 175 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)